Market news

DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing uni...

Humacyte, Inc. (HUMA) reached $0.59 at the closing of the latest trading day, reflecting a +2.23% change compared to its last close.

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on September 16, 2026, at 11:00am Eastern Time. Management will also b

– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all established quality specifications throughout the 36-month dating period – DURHAM, N.C., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that the U.S. Food and Drug Administration (FDA) has a

Humacyte (HUMA) said Wednesday the US Food and Drug Administration has authorized an extension of th

– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 – – Supplemental BLA will be supported by results from three Phase 3 studies of ATEV, including results from V012 dialysis access study in women – – The V012 dialysis access study found that women who received Humacyte's ATEV experienced an average of three more months without a dialysis catheter than women who received AV fistula, the current standard of care – DU

Humacyte (HUMA) said Monday it plans to file in November a supplemental biologics license applicatio

– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes –

Humacyte earnings update and stock context Humacyte (HUMA) reported second quarter 2026 results that included revenue of US$0.406 million and a net loss of US$36.8 million, alongside recent Nasdaq compliance pressure after its share price stayed below US$1.00. For the first half of 2026, the company reported revenue of US$0.901 million and a net loss of US$54.42 million. Earnings per share moved from a small profit a year ago to a basic loss of US$0.25 from continuing operations. Humacyte...

Humacyte stock has had a very rough run over the last several years, and current valuation checks now lean toward the shares looking expensive rather than like a clear bargain. Humacyte has declined 93.3% over the past 5 years, which puts recent pricing in the context of a very long and deep drawdown for existing shareholders. Recent progress in tissue engineered vessel programs and regulatory milestones may support expectations for future revenue, while the risk that clinical or regulatory...

Humacyte (NasdaqGS:HUMA) reported Phase 3 dialysis access data showing its acellular tissue engineered vessel outperformed standard of care for female patients. The company plans to file a supplemental Biologics License Application based on the female cohort results from the dialysis access trial. The FDA accepted an Investigational New Drug application for Humacyte’s new coronary vessel candidate, allowing clinical development to proceed. This progress at Humacyte is part of a wider push...

Moby summary of Humacyte, Inc.'s Q2 2026 earnings call

Humacyte (NASDAQ:HUMA) reported second-quarter commercial sales growth while outlining plans to expand adoption of its SYMVESS vascular repair product, submit a supplemental biologics license application for dialysis access and begin a first-in-human coronary bypass study. Commercial sales totaled

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -60.00% and -70.79%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with the Food and Drug Administration (FDA) during the second half of 2026 – – FDA accepted IND for first-in-human clinical study of CTEV for CABG with Phase 2a study expected to start Q3 2026 – – Second quarter sales of Symvess® were $0.4 million in 2026 compared to $0.1 million in 2025 – – Conference c

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.73, signifying a +2.33% move from its prior day's close.

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.63, signifying a -6.44% move from its prior day's close.

Humacyte (HUMA) said Monday that the US Food and Drug Administration has accepted its investigationa

– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter – – Progression of CTEV into human study supported by positive preclinical results presented at multiple scientific meetings and in a recent publication – DURHAM, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that the Food and Drug

In the latest trading session, Humacyte, Inc. (HUMA) closed at $0.67, marking a +2.22% move from the previous day.

Humacyte, Inc. (HUMA) closed at $0.66 in the latest trading session, marking a -1.28% move from the prior day.

Humacyte, Inc. (HUMA) closed the most recent trading day at $0.71, moving +2.31% from the previous trading session.